Total Results: 16191

Drug Puts A $750,000 ‘Price Tag On Life’

KHN Original

The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.

CMS To Cut Billions In Aid To Hospitals That Care For Nation’s Most Vulnerable Populations

KHN Morning Briefing

The cuts, which are focused on what’s known as disproportionate-share hospital funds meant to help hospitals with uncompensated care costs, were supposed to start in 2014 under the Affordable Care Act but have been delayed. The reductions were put in place because the ACA’s coverage expansions were expected to reduce the demand for such charity care. But many institutions face tabs for uncompensated care that exceed those projections.